Natixis Advisors LLC Has $5.74 Million Holdings in Integer Holdings Co. (NYSE:ITGR)

Natixis Advisors LLC cut its holdings in Integer Holdings Co. (NYSE:ITGR) by 3.9% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 43,278 shares of the medical equipment provider’s stock after selling 1,770 shares during the quarter. Natixis Advisors LLC’s holdings in Integer were worth $5,735,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in ITGR. Mather Group LLC. lifted its stake in Integer by 304.3% in the fourth quarter. Mather Group LLC. now owns 190 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 143 shares during the period. R Squared Ltd acquired a new position in Integer in the fourth quarter valued at approximately $44,000. Versant Capital Management Inc lifted its stake in Integer by 98.4% in the fourth quarter. Versant Capital Management Inc now owns 369 shares of the medical equipment provider’s stock valued at $49,000 after buying an additional 183 shares during the period. Principal Securities Inc. lifted its stake in Integer by 31.2% in the fourth quarter. Principal Securities Inc. now owns 639 shares of the medical equipment provider’s stock valued at $85,000 after buying an additional 152 shares during the period. Finally, Contravisory Investment Management Inc. lifted its stake in Integer by 210.8% in the fourth quarter. Contravisory Investment Management Inc. now owns 693 shares of the medical equipment provider’s stock valued at $92,000 after buying an additional 470 shares during the period. 99.29% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on ITGR shares. Citigroup upped their target price on Integer from $130.00 to $145.00 and gave the stock a “neutral” rating in a research report on Wednesday, December 11th. Benchmark upped their target price on Integer from $140.00 to $150.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Truist Financial upped their target price on Integer from $147.00 to $163.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. KeyCorp upped their target price on Integer from $144.00 to $154.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Finally, Oppenheimer lowered Integer from an “outperform” rating to a “market perform” rating in a research report on Friday, February 21st. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $149.00.

Integer Trading Down 1.0 %

Shares of Integer stock opened at $115.07 on Friday. The stock has a fifty day simple moving average of $132.59 and a 200 day simple moving average of $132.31. Integer Holdings Co. has a 12-month low of $107.11 and a 12-month high of $146.36. The company has a market capitalization of $3.87 billion, a P/E ratio of 34.25, a price-to-earnings-growth ratio of 1.72 and a beta of 1.24. The company has a current ratio of 2.95, a quick ratio of 2.09 and a debt-to-equity ratio of 0.62.

Integer (NYSE:ITGR) last announced its quarterly earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.46 by ($0.03). Integer had a return on equity of 11.65% and a net margin of 6.92%. The company had revenue of $449.50 million for the quarter, compared to the consensus estimate of $446.28 million. On average, sell-side analysts anticipate that Integer Holdings Co. will post 6.01 earnings per share for the current fiscal year.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.